AI Stock Analysis - Aldeyra Therapeutics (ALDX)
Analysis generated December 4, 2025.
Aldeyra Therapeutics, Inc. (ALDX) is a clinical-stage biotechnology company dedicated to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's most advanced product candidates are designed to treat conditions ranging from allergic conjunctivitis to rare diseases, leveraging its proprietary aldehyde-sequestration platform. Given its innovative pipeline and focus on unmet medical needs, Aldeyra presents itself as a high-potential player in the biotech sector.
Stock Alerts - Aldeyra Therapeutics (ALDX)
 |
Aldeyra Therapeutics | March 5 Price is down by -6.1% in the last 24h. |
|
Aldeyra Therapeutics | March 3 Price is down by -6.1% in the last 24h. |
|
Aldeyra Therapeutics | February 25 Price is up by 6.9% in the last 24h. |
|
Aldeyra Therapeutics | February 24 Price is up by 6.6% in the last 24h. |
Download our app to get future alerts delivered in real-time.
Alternative Data for Aldeyra Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 64 | Sign up | Sign up | Sign up |
| Webpage traffic | 3,000 | Sign up | Sign up | Sign up |
| Employee Rating | 100 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | N/A | Sign up | Sign up | Sign up |
| Facebook Followers | 843 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 164 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 8,361 | Sign up | Sign up | Sign up |
| X Followers | 476 | Sign up | Sign up | Sign up |
| X Mentions | 12 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 100 | Sign up | Sign up | Sign up |
| Linkedin Employees | 15 | Sign up | Sign up | Sign up |
About Aldeyra Therapeutics
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases.
| Price | $4.55 |
| Target Price | Sign up |
| Volume | 436,490 |
| Market Cap | $307M |
| Year Range | $3.51 - $5.89 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Does Aldeyra Therapeutics (ALDX) Have the Potential to Rally 79.28% as Wall Street Analysts Expect?February 18 - Yahoo |
|
Aldeyra Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences ConferenceFebruary 17 - Yahoo |
Atopic Dermatitis Competitive Landscape Report 2026: Comprehensive Insights About 100+ Companies and 110+ DrugsFebruary 18 - GlobeNewswire |
|
Asthma Market Competitive Landscape Report 2026: Comprehensive Insights About 110+ Companies and 125+ DrugsFebruary 18 - GlobeNewswire |
|
Catalyst Monitor Report: Q1 2026 Outlook: Regulatory Approvals and Late-Stage Trials Signal Strong Pipeline Momentum Across Key Therapeutic AreasJanuary 20 - GlobeNewswire |
|
|
ATA Creativity Global Among 3 Promising Penny StocksJanuary 19 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 0 | 64,000 | -64,000 | -7.7M | -7.1M | -0.130 |
| Q2 '25 | 0 | 62,000 | -62,000 | -9.8M | -9.2M | -0.160 |
| Q1 '25 | 0 | 61,000 | -61,000 | -9.9M | -9.4M | -0.170 |
| Q4 '24 | 240,000 | 64,000 | -64,000 | -16M | -15M | -0.270 |
| Q3 '24 | 0 | 63,000 | -63,000 | -15M | -15M | -0.250 |
Insider Transactions View All
| Alfieri Michael filed to buy 2,500 shares at $5.3. August 15 '25 |
| Machatha Stephen filed to sell 221,799 shares at $5.2. August 13 '25 |
| EDELMAN JOSEPH filed to sell 5,875,851 shares at $1.4. April 7 '25 |
| Greenberg Bruce filed to sell 126,382 shares at $4.7. August 14 '24 |
| Machatha Stephen filed to sell 236,771 shares at $4.7. August 14 '24 |
Similar companies
Read more about Aldeyra Therapeutics (ALDX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - Aldeyra Therapeutics
The Market Cap of Aldeyra Therapeutics is $307M.
Currently, the price of one share of Aldeyra Therapeutics stock is $4.55.
The ALDX stock price chart above provides a comprehensive visual representation of Aldeyra Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Aldeyra Therapeutics shares. Our platform offers an up-to-date ALDX stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Aldeyra Therapeutics (ALDX) does not offer dividends to its shareholders. Investors interested in Aldeyra Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Aldeyra Therapeutics are Anavex Life Sciences, BridgeBio Pharma, Crispr Therapeutics, Editas Medicine, and Amarin.
